Vita 34 AG announces preliminary, unaudited results for the fiscal year 2013

Leipzig, (PresseBox) - Vita 34 AG (WKN A0BL84), the largest private stem cell bank in the Germanspeaking countries, announces preliminary, unaudited results according to the International Reporting Standards (IFRS) for the fiscal year 2013. For the fiscal year 2013 Vita 34 AG expects to generate revenue on about the same level of the previous year with 13.6 million Euro (2012: 13.6 million Euro) and earnings before interest, taxes, depreciation and amortization (EBITDA) of approximately 2.7 million Euro (2012: 0.4 million Euro) and thus exceeds the estimation published on 24 October 2013.

VITA 34 AG Deutschland

Vita 34 was founded in 1997 as the first private umbilical cord blood bank in Europe and as a fullservice provider takes care of the collection logistics, processing, and storage of umbilical cord blood and umbilical cord tissue. Its successful operation is based on an excellent position in the technological segment of cryo-preservation. Cells and tissue are kept alive at temperatures around minus 190 degrees Celsius and can be applied in medical therapies if required. Parents of approximately 100,000 children already make use of this offer and have taken provisions for their children by means of a stem cell depot at the company from Leipzig.

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.